Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:SYK
Stryker Corp. (SYK)
307.00
-0.80 (0.26%)
as of Jun 18, 2026, 8:52:16 pm Market Open.
184 watching
Financials 
Technical Analysis 0
TOP PICK
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Paul MacDonaldOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
Barry SchwartzOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
Zachary Curry Owned
biotechnologypharmaceutical
TOP PICK
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PARTIAL BUY
They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.
David DriscollOwned
biotechnologypharmaceutical
BUY
Allan Tong’s Discover Picks Stryker enjoyed a bounce after beating Q2 revenues and earnings a month ago, but has been rangebound between $180 and $205 since Easter. Typical of the other medical device stocks here, it has yet to return to pre-COVID highs of $226, but trades at a 27.44x PE, far more reasonable than peers including Intuitive Surgical. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
Stockchase DiscoverOwned
biotechnologypharmaceutical
BUY
Medical devices have had a tough year, as elective surgeries have been put on hold. Will continue to do well as surgeries come back. Steep learning curve when it comes to these products, so that's a risk. But once doctors learn the mechanics, they're repeat users. Demographic play. At a good level here.
biotechnologypharmaceutical
BUY
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
biotechnologypharmaceutical
BUY
He just bought a huge chunk this morning. A company that makes medical devices and is the leader in hips, knees and shoulder replacement. The sales force is their moat. It is able to pivot really quickly. They produce the best products, makes good acquisitions and deploys cash well.
Barry SchwartzOwned
biotechnologypharmaceutical
TOP PICK
They make medical and surgical equipment in orthopedics. They just bought a hands-and-ankles medical company. Most elective surgeries were postponed in the pandemic, but are slowly coming back now which benefits SYK. Salespeople are very knowledgeable about their products. Doctors remain loyal to SYK's products and won't switch to another company. (Analysts’ price target is $205.79)
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
A medical device company. Elective surgeries have been slowed during the pandemic, but will still need to done. Demographics mean this will continue to grow. There is brand loyalty in the space as parts are not easily exchangeable. About 25% of cash flow goes to dividends and the rest towards acquisitions and paying down debt. Yield 1.31% (Analysts’ price target is $205.63)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 21/19, Up 4%) It is a good opportunity to buy the stock right here. Elective surgeries are shut down and have to come back. You may have tougher quarters over the next little while.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jun 04/19, Down 7%) He really likes the equipment side of the healthcare industry. There is a bit of a lag for the kind of procedures they are doing. The demographic is really good and people will continue to need knees and hips and so on. He is looking to add more to this industry. He continues to hold it.
Zachary Curry Owned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
